Werewolf Therapeutics (HOWL)

• Market cap: $59M
• 1 day: -7.86%
• 5 days: -28.73%
• 1 month: -34.52%
• 3 months: 6.61%
• 6 months: 42.97%
• Year to date: -17.31%
• 1 year: -49.61%
• 5 years: -91.99%
• 10 years: -91.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Employees: 46